Apogenix (Germany) a clinical-stage biopharmaceutical company focused on modulators of apoptosis and IL-4 signaling for glioblastoma and other cancers, graft versus host disease and inflammatory diseases, closed a $10M Series C financing. Participants include Dievini Hopp BioTech.